This view has evolved through studies correlating EGFR expression with disease progression in multiple tumour types (Sainsbury et al, 1987; Salomon et al, 1995; Maurizi et al, 1996; Dong et al, 1998) and evidence that EGFR-inhibition can influence a diverse range of pathways, including those involved in proliferation, reduced apoptosis, angiogenesis and invasion (Woodburn, 1999). The gene discussed is EGFR; the disease is neoplasm.